Royalty Report: Drugs, Pain, Cannabis – Collection: 238985

License Grant

Licensor grants an exclusive license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market, commercialize, distribute and sell and otherwise dispose of Compound and Product for all uses in the Territory.

License Property

The Licensor has rights to patents including (3R,4R)-Delta -Tetrahydrocannabinol – 7-OIC Acids, and, (3R,4R)-Delta – Tetrahydrocannabinol- 11 -OIC Acids useful as anti-inflammatory agents and analgesics.  

Compound shall mean the chemical compounds known as (3R, 4R) Delta 6-Tetrahydrocannabinol -7-oic Acids, including the compound designated CT-3, and any other compounds disclosed or covered in the Patent Assets and any derivative, homo log, or analog of any of the foregoing, and any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing.

CT-3, a new chemical entity also known as ajulemic acid, is a non-psychoactive synthetic derivative of tetrahydrocannabinol (THC).

Field of Use

Field shall mean all potential fields of use of the Patents Rights, the Licensed Products, and the Licensed Processes.  The  compound is anti-inflammatory and analgesic.

License Grant

The Transaction with the patent holder, an individual, is for the structure of CT-3, a synthetic derivative of carboxylic tetrahydrocannabinol (THC-7C) hoped to be an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) for pain.

License Property

CT-3 was designed to maximize the potent efficacious medicinal properties of cannabis, without producing undesirable psychiatric side effects.

An Investigational New Drug (IND) application for CT-3 was successfully filed with the United States Food and Drug Administration and a Phase I Clinical Trial has been successfully completed.

Field of Use

The Field of Use relates to the medical industry.

License Grant

The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.

License Property

The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use

Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

License Grant

The French Licensor grants an exclusive, even as to Licensor, license under Licensor Intellectual Property, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market, commercialize, distribute, sell or otherwise dispose of Compound and Product for all uses in the Territory.

License Property

The patents incllude Echinocanoine Fongicide and the chemical compound HMR 3270.

The Deoxymulundocandin nucleus standard K91 is not fully characterized yet.

Compound shall mean the chemical compound known under the International Nonproprietary name aminocandin and the code name HMR-3270, and any other compounds disclosed or covered or included in the Licensor Patent Assets or any compound that is part of the aminocandin family of compounds or any derivative, homolog, or analog of any of the foregoing, and any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing that exists and is owned or controlled by Licensor as of the Effective Date.

Nucleus shall mean deacylmulundocandin, the starting material for the manufacture of the Compound, obtained by biochemistry through a biosynthesis from an Aspergillus strain, the first step of which leads to deoxymulundocandin and the second step of which leads to deacylmulundocandin.

“Compound” shall mean the chemical compound known under the International Non-proprietary name aminocandin and the code name HMR-3270.

Field of Use

Aminocandin is an echinocandin, a new class of anti-fungal compounds in development for the treatment of a broad spectrum of systemic, invasive fungal infections.

License Grant

The Licensor of Switzerland and the Licensee now desire to modify their arrangements under the Original Agreement to provide, among other things, for the relinquishment of the sublicenses and licenses granted by Licensor to Licensee under the Original Agreement in the U .S./Canadian Territory, for the grant by Licensee to Licensor of exclusive license rights with respect to certain Licensee Know-How and Licensee Trademarks and for the assignment by Licensee to Licensor of the Existing Applications and Approvals and the Licensee Domain Names.

The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents licensed to Licensor or its Affiliates and an Exclusive license in the Field under the Patents, except for the Biomarker Patent, owned by Licensor or its Affiliates,  an Exclusive sublicense and license, as applicable, in the Field under the Know-How and a non-exclusive license in the Field under the Patent owned by Licensor covering the biomarker, in each case, to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the ROW Territory,

Licensor grants a non-exclusive, ROW Territory sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product, not listed, which may be claimed in Patents in the ROW Territory limited solely to making or using the Compound or Product.

License Property

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is I-[ 4-[3 -[ 4-( 6-fluoro-1,2-benzisoxazol-3-y 1 )-1-piperidiny l] propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.

Depot Formulation shall mean any extended-release, injectable formulation of the Compound.

The parties acknowledge and agree that Products sold within the United States will be sold only under the  trademark FANAPTâ„¢.

Field of Use

Field shall mean application to all conditions, disorders and diseases in humans.  The licensed patents field of use is as antipsychotic drugs.

License Grant

The Israeli Licensor, the technology transfer company of the University, granted Licensee a worldwide exclusive license to develop and commercialize certain patents, know-how and research results (collectively, the 2018 Hebrew Licensed Technology), in order to develop, manufacture, market, distribute or sell products, all within the use of the 2018 Hebrew Licensed Technology.

License Property

Licensor will undertake research and to synthesize chemical compounds that will be used by Licensee, through additional research at two Universities, to develop orally active analgesic and anti-inflammatory medications. Compounds will be shipped from University to Oxford for use in pre-clinical studies to establish efficacy in pain and inflammation.

Field of Use

This agreement pertains to the drug industry for the treatment of any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the 2018 Field).

The license is to develop and commercialize certain patents in order to develop, manufacture, market, distribute, sell, repair and refurbish products, all within the use of the 2019 Hebrew Licensed Technology for (i) Cannabinoid phenolate metal salts, including mono, di and trivalent metals such as Li, Na, K, Ca, Mg, Zn, Fe and Al and their mixtures with native or synthetic cannabinoids, their pharmaceutical formulations, including for oral and topical administration; and (ii) pharmaceutical formulations, for the administration of cannabinoid chemical derivatives, including any and all veterinary and human medical conditions, including obesity, pain, inflammation and arthritis (the “2019 Field”).